Diabetic Neuropathy News and Research RSS Feed - Diabetic Neuropathy News and Research

Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.
‘Reassuring’ findings on microvascular risk in diabetic statin users

‘Reassuring’ findings on microvascular risk in diabetic statin users

Statin treatment prior to diabetes onset does not appear to increase the risk of microvascular disease and may even be protective against some forms, findings from a registry study suggest. [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]
BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences International, Inc. announced today that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). [More]
NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]
NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the marketing launch in Japan of NC-stat® DPNCheck®. [More]
Sheffield professor awarded prestigious Camillo Golgi Prize for outstanding contribution to medicine

Sheffield professor awarded prestigious Camillo Golgi Prize for outstanding contribution to medicine

A CONSULTANT who first described how diabetic nerve damage is caused by impaired circulation of the nerves has been awarded one of the most coveted international prizes in medicine in recognition of his outstanding contribution to the field. [More]
Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

New research published today out of the University of Calgary's Hotchkiss Brain Institute uncovers a mechanism to promote growth in damaged nerve cells as a means to restore connections after injury. Dr. Doug Zochodne and his team have discovered a key molecule that directly regulates nerve cell growth in the damaged nervous system. [More]
BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. [More]
Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. [More]

NC-stat DPNCheck is a fast, accurate point-of-care test for diabetic peripheral neuropathy

NeuroMetrix, Inc. (the "Company"), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto. [More]
New pain management system for patients with painful diabetic neuropathy

New pain management system for patients with painful diabetic neuropathy

From the moment people learn to walk, many are taught that exercise is the key to living a healthy life. Indeed, the long-term benefits of exercise are indisputable. [More]
Scientists identify channel that acts as 'brake', limiting spontaneous pain

Scientists identify channel that acts as 'brake', limiting spontaneous pain

Scientists have identified a channel present in many pain detecting sensory neurons that acts as a 'brake', limiting spontaneous pain. It is hoped that the new research, published today [22 January] in the Journal of Neuroscience, will ultimately contribute to new pain relief treatments. [More]
Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath, Inc., the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy. [More]
Ohio State's Wexner Medical Center neurosurgeons implant MRI-safe spinal cord stimulator for pain

Ohio State's Wexner Medical Center neurosurgeons implant MRI-safe spinal cord stimulator for pain

Neurosurgeons at The Ohio State University Wexner Medical Center are among the first in the United States to successfully implant an MRI-safe spinal cord stimulator to help patients suffering from chronic back or limb pain. [More]
NeuroMetrix announces business and financial highlights for second quarter

NeuroMetrix announces business and financial highlights for second quarter

NeuroMetrix, Inc. (the "Company"), a medical device company focused on the treatment of the neurological complications of diabetes, today reported business and financial highlights for the second quarter ended June 30, 2013. [More]
Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia. [More]
NACC recommendations address established pain therapies and preview potential future advances

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances. [More]

BioDelivery Sciences International submits BUNAVAIL NDA to FDA

BioDelivery Sciences International, Inc. announced today that it engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BUNAVAIL for the maintenance treatment of opioid dependence. [More]
Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries. [More]